Skip to contentW
West Pharmaceutical Services Inc
W
WSTWest Pharmaceutical Services Inc Q4 2014 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$349.80M$349.80Mderived+2.1% vs Q4 2013 Net Income$31.40M$31.40Mderived+33.1% vs Q4 2013 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
West Pharmaceutical Services Inc · CIK 105770 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$109,700,000+2.9% Operating Incomederived$44,600,000+20.9% Operating Cash Flowderived$46,000,000−33.1% Free Cash Flowderived$18,900,000−37.0% Margins · derivedGross margin31.4%+0.3 pt vs Q4 2013
Operating margin12.8%+2.0 pt vs Q4 2013
Net margin9.0%+2.1 pt vs Q4 2013
ended Dec 31, 2014 · filed Feb 25, 2015 · 56 d after period end